BioLight Life Sciences Ltd. [TASE BOLT] is the only company in Israel investing solely in Ophthalmology. BioLight’s current and future portfolio companies engage in advanced medical devices, medication, diagnostics and digital healthcare, exemplifying the enormous potential of “ Israeli Innovation in Ophthalmology” with a special focus on converging Ophthalmology with Engineering.
The need for Innovation in Ophthalmology
Population growth and aging worldwide, as well as the environment’s increasing factors harming eye health (UV exposure, computer screens etc.) escalate the need for innovative and effective solutions for the treatment of eye diseases.
Development and commercialization of the company’s ophthalmic technologies and products
The ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and technological advancements. Several of our ophthalmic products are in various commercialization and clinical (or pre-clinical) phases.
More on our Portfolio Companies
DiagnosTear’s TeaRx™ DiagnosTear’s TeaRx™ technology is a diagnostic platform intended for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops.
LipiCare is currently launching its proprietary Ocular D product. The only nano emulsion daily dosage with Vitamin D that filters blue light and therefore provides a premium product to treat dry eye and digital eye strain. CE approved.
ViSci is innovative Eye D technology treats glaucoma by the insertion of a sub conjunctival implant, which releases the medication Latanaprost ””, in sustained release manner, eliminating the need to use drops. Successfully completed Phase I/Ii a in US and ready for 505 ( 2 ) enabling study.
OphRx engages in the development of drugs for treating eye diseases using an innovative technological platform that enhances the transmission of active substances based on nanostructures.
Peripherex develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment, used by eye care and other providers to diagnose and monitor glaucoma and other diseases.
AEYE develops artificial intelligence (AI) solutions for a variety of retinal diseases.
Tarsier develops an innovative product, the TRS 01, based on its technological platform for the treatment of Uveitis in patients suffering from high IPO.
Belkin Vision develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP.
Sanoculis develops an innovative surgical procedure for the treatment of the Glaucoma.
A word to our investors
BioLight intends, in line with its financial capabilities, to continue supplementing and expanding the array of technologies and products under development, whether through investment in additional companies or through business development and expansion of the activity of the existing companies.
BioLight was incorporated in Israel and is a public company traded on the Tel Aviv Stock Exchange (TASE: BOLT).